Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.210
+0.010 (0.83%)
At close: Jun 18, 2026, 4:00 PM EDT
1.203
-0.007 (-0.60%)
After-hours: Jun 18, 2026, 4:22 PM EDT
Entera Bio Revenue
In the year 2025, Entera Bio had annual revenue of $42.00K, down -76.80%.
Revenue (ttm)
$42.00K
Revenue Growth
-76.80%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
59.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.00K | -139.00K | -76.80% |
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 9.14M |
| ImageneBio | 800.00K |
| MediciNova | 596.64K |
| iBio, Inc. | 300.00K |
| Impact BioMedical | 39.00K |
| eXoZymes | -700.00 |
ENTX News
- 2 days ago - Entera Bio and Opko Health present preclinical data for oral peptides - TheFly
- 2 days ago - Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 - GlobeNewsWire
- 3 days ago - ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) - GlobeNewsWire
- 15 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 15 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 21 days ago - Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation - GlobeNewsWire
- 5 weeks ago - Entera Bio Proxy statement: Proxy filing - Filings
- 5 weeks ago - Entera Bio files to sell 19.57M ordinary shares for holders - TheFly